Depression Clinical Trial
Official title:
An Investigation to Determine Whether Levels of P11 Protein in Peripheral Blood Cells Correlate With Treatment Response to Citalopram in Patients With Major Depressive Disorder
NCT number | NCT00697268 |
Other study ID # | 080150 |
Secondary ID | 08-M-0150 |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 3, 2008 |
Est. completion date | July 28, 2016 |
Verified date | July 28, 2016 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will compare levels of p11 protein in people with and without major depressive
disorder (MDD) and examine if p11 levels in patients are affected by treatment with
citalopram (Celexa).
Healthy normal volunteers and patients with chronic or recurrent major depression between 18
and 65 years of age may be eligible for this study.
Participants undergo the following tests and procedures:
Healthy Volunteers
- Psychiatric interview and medical examination, questions about family history
- Blood draw
Patients with MDD
Phase 1 - Evaluation and Discontinuation of Medications
- Physical examination, electrocardiogram, blood tests
- Gradual antidepressant medication withdrawal, followed by 2- to 6-week drug-free period.
If needed, medicines for anxiety and difficulty sleeping may be prescribed.
Phase 2 Citalopram Treatment
- Start daily citalopram treatment
- Evaluations at the start of phase 2 and every week for 8 weeks with following
procedures:
- Symptoms ratings interview and questionnaires
- Review of side effects and new medications
- Blood pressure and pulse measurements
- Blood and urine tests
At the end of the study, plans are developed for long-term treatment and transfer of care to
the patient s own physician.
...
Status | Completed |
Enrollment | 38 |
Est. completion date | July 28, 2016 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: CRITERIA FOR INCLUSION OF DEPRESSED PATIENTS: - age 18-65 years - written informed consent completed (consent-incapacitated subjects will not be eligible) - score 20 or higher on the Montgomery-Asberg Depression Rating Scale (MADRS) - meets DSM-IV criteria for chronic or recurrent nonpsychotic MDD - patients who are on non-excluded concomitant medications. - no more than 3 failed antidepressant treatments within the current major depressive episode - no alcohol use (last 7 days) ADDITIONAL CRITERIA FOR INCLUSION OF DEPRESSED PATIENTS FOR MRI IMAGING: - age 18 55 years - subjects must have either a family history of mood disorders, or have a history of multiple major depressive episodes - age of onset of depressive symptoms less than 45 years - no history of past alcohol or substance dependence (excluding nicotine) or alcohol or substance abuse (excluding nicotine) within the past year. - no use of benzodiazepines within 2 weeks of either MRI scan CRITERIA FOR INCLUSION OF HEALTHY CONTROL SUBJECTS: - age 18-65 years - written informed consent completed - no current or past diagnosis of axis I psychiatric disorder (DSM-IVTR) - no alcohol use (last 7 days) - physically healthy ADDITIONAL CRITERIA FOR INCLUSION OF HEALTHY CONTROL SUBJECTS FOR MRI IMAGING: - age 18 55 years - no history of past alcohol or substance dependence (excluding nicotine) or alcohol or substance abuse (excluding nicotine) within the past year. EXCLUSION CRITERIA: CRITERIA FOR EXCLUSION OF DEPRESSED PATIENTS: - history of bipolar disorder (I, II, or NOS) (lifetime) - history of schizophrenia - history of schizoaffective disorder or - psychosis NOS (lifetime) - history of anorexia nervosa or bulimia nervosa (lifetime) - current primary obsessive-compulsive disorder (OCD) or current post traumatic stress disorder (PTSD) whose onset preceded the onset of Major Depressive Disorder - history of clear-cut intolerability to the study medication - lack of response to an adequate trial of the study medication (citalopram) in the current or past episodes of MDD - did not respond to 7 or more sessions of ECT in the current episode of MDD - Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. - has general medical condition which contraindicates the use of the study medication - is on concomitant medication which contraindicates the use of the study medication - requires immediate hospitalization for psychiatric disorder - requires antipsychotic medications or mood stabilizers - Non-postmenopausal (less than 2 years since last period) females of childbearing potential who are sexually active and who are not using adequate (hormonal, double barrier, surgical) contraception, or who are pregnant or breast feeding - patients currently taking any of the exclusionary medications detailed in protocol (including antipsychotic medications, anticonvulsant medications, antidepressant medications, mood stabilizers, central nervous system stimulants) in the 2 weeks prior to Study Period II. - patients taking thyroid medication for hypothyroidism may be included if they have been stable on the medication for greater than 3 months - patients can participate in a modality of psychotherapy that is not targeting the symptoms of depression (e.g., supportive therapy, marital therapy) - therapy that is depression specific, such as Cognitive Therapy (CT) or Interpersonal Psychotherapy of Depression (IPT) is not allowed during participation - subjects must be fluent in English and have the capacity to understand the nature of the study and sign the written informed consent. - current alcohol dependence or abuse (last 3 months) - patient has a prolonged QTc (greater than or equal to 450 msec), as shown on ECG - Current NIMH employee/staff or their immediate family member. ADDITIONAL CRITERIA FOR EXCLUSION OF DEPRESSED PATIENTS FOR MRI IMAGING: - subjects meeting general exclusion criteria for MRI scanning (e.g. implanted cardiac pacemaker, intraocular metal) will be excluded from the MRI procedures only. - subjects with structural lesions visible on MRI will be excluded from further MRI procedures - subjects with diabetes or hypertension will be excluded CRITERIA FOR EXCLUSION OF HEALTHY CONTROL SUBJECTS: - subjects currently taking any of the exclusionary medications detailed in protocol in the 2 weeks prior to evaluation - current alcohol dependence or abuse (last 3 months) - history of major depression or bipolar disorder in any first degree relative ADDITIONAL CRITERIA FOR EXCLUSION OF HEALTHY CONTROL SUBJECTS: - subjects meeting general exclusion criteria for MRI scanning (e.g. implanted cardiac pacemaker, intraocular metal) will be excluded from the MRI procedures only. - subjects with structural lesions visible on MRI will be excluded from further MRI procedures - subjects with diabetes or hypertension will be excluded |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999 Aug;38(8):1083-152. Review. — View Citation
Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003 Dec;64(12):1465-75. — View Citation
Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russo J. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA. 1995 Apr 5;273(13):1026-31. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | We will study whether blood cell levels of p11 differ between healthy individuals and patients with depression. Moreover, we will study whether the levels of p11 are affected by treatment with the selective serotonin reuptake inhibitor, citalopr... | Baseline, +1 week, +2 weeks, +3 weeks, +4 weeks, +5 weeks, +6 weeks, +7 weeks, +8 weeks | ||
Secondary | Complementary work will continue at other laboratories to better characterize the role of p11 in the pathophysiology of depression (e.g., animal studies, post-mortem studies). | Baseline, +1 week, +2 weeks, +8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |